Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis
Schistosomiasis is a major neglected parasitic disease that affects more than 240 million people worldwide and for which the control strategy consists of mass treatment with the only available drug, praziquantel. Schistosomes display morphologically distinct stages during their life cycle and the tr...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-01-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/15/1/80 |
| _version_ | 1797491311349071872 |
|---|---|
| author | Ehab Ghazy Mohamed Abdelsalam Dina Robaa Raymond J. Pierce Wolfgang Sippl |
| author_facet | Ehab Ghazy Mohamed Abdelsalam Dina Robaa Raymond J. Pierce Wolfgang Sippl |
| author_sort | Ehab Ghazy |
| collection | DOAJ |
| description | Schistosomiasis is a major neglected parasitic disease that affects more than 240 million people worldwide and for which the control strategy consists of mass treatment with the only available drug, praziquantel. Schistosomes display morphologically distinct stages during their life cycle and the transformations between stages are controlled by epigenetic mechanisms. The targeting of epigenetic actors might therefore represent the parasites’ Achilles’ heel. Specifically, histone deacetylases have been recently characterized as drug targets for the treatment of schistosomiasis. This review focuses on the recent development of inhibitors for schistosome histone deacetylases. In particular, advances in the development of inhibitors of <i>Schistosoma mansoni</i> histone deacetylase 8 have indicated that targeting this enzyme is a promising approach for the treatment of this infection. |
| first_indexed | 2024-03-10T00:44:42Z |
| format | Article |
| id | doaj.art-fc809c6dd58441428daa3923930df3b7 |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-10T00:44:42Z |
| publishDate | 2022-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-fc809c6dd58441428daa3923930df3b72023-11-23T15:01:45ZengMDPI AGPharmaceuticals1424-82472022-01-011518010.3390/ph15010080Histone Deacetylase (HDAC) Inhibitors for the Treatment of SchistosomiasisEhab Ghazy0Mohamed Abdelsalam1Dina Robaa2Raymond J. Pierce3Wolfgang Sippl4Department of Medicinal Chemistry, Institute of Pharmacy, Martin-Luther-University of Halle-Wittenberg, 06120 Halle (Saale), GermanyDepartment of Medicinal Chemistry, Institute of Pharmacy, Martin-Luther-University of Halle-Wittenberg, 06120 Halle (Saale), GermanyDepartment of Medicinal Chemistry, Institute of Pharmacy, Martin-Luther-University of Halle-Wittenberg, 06120 Halle (Saale), GermanyCentre d’Infection et d’Immunité de Lille, U1019—UMR9017—CIIL, Institute Pasteur de Lille, CNRS, Inserm, CHU Lille, Univ. Lille, F-59000 Lille, FranceDepartment of Medicinal Chemistry, Institute of Pharmacy, Martin-Luther-University of Halle-Wittenberg, 06120 Halle (Saale), GermanySchistosomiasis is a major neglected parasitic disease that affects more than 240 million people worldwide and for which the control strategy consists of mass treatment with the only available drug, praziquantel. Schistosomes display morphologically distinct stages during their life cycle and the transformations between stages are controlled by epigenetic mechanisms. The targeting of epigenetic actors might therefore represent the parasites’ Achilles’ heel. Specifically, histone deacetylases have been recently characterized as drug targets for the treatment of schistosomiasis. This review focuses on the recent development of inhibitors for schistosome histone deacetylases. In particular, advances in the development of inhibitors of <i>Schistosoma mansoni</i> histone deacetylase 8 have indicated that targeting this enzyme is a promising approach for the treatment of this infection.https://www.mdpi.com/1424-8247/15/1/80schistosomiasisepigeneticsmHDAC8hydroxamic acidsHDAC inhibitorssirtuins |
| spellingShingle | Ehab Ghazy Mohamed Abdelsalam Dina Robaa Raymond J. Pierce Wolfgang Sippl Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis Pharmaceuticals schistosomiasis epigenetic smHDAC8 hydroxamic acids HDAC inhibitors sirtuins |
| title | Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis |
| title_full | Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis |
| title_fullStr | Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis |
| title_full_unstemmed | Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis |
| title_short | Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis |
| title_sort | histone deacetylase hdac inhibitors for the treatment of schistosomiasis |
| topic | schistosomiasis epigenetic smHDAC8 hydroxamic acids HDAC inhibitors sirtuins |
| url | https://www.mdpi.com/1424-8247/15/1/80 |
| work_keys_str_mv | AT ehabghazy histonedeacetylasehdacinhibitorsforthetreatmentofschistosomiasis AT mohamedabdelsalam histonedeacetylasehdacinhibitorsforthetreatmentofschistosomiasis AT dinarobaa histonedeacetylasehdacinhibitorsforthetreatmentofschistosomiasis AT raymondjpierce histonedeacetylasehdacinhibitorsforthetreatmentofschistosomiasis AT wolfgangsippl histonedeacetylasehdacinhibitorsforthetreatmentofschistosomiasis |